PPARG and hepatocellular carcinoma: Here, we show for the first time that PPARγ phosphorylation at Ser84/Ser82 (Ser112 in PPARγ2) occurs in the majority of HCC cases investigated and in liver tumours from human samples and a mouse model, whereas blockade of PPARγ phosphorylation by a kinase inhibitor or site-mutation both decrease the aggressiveness and tumourigenicity of hepatoma/hepatocarcinoma cells.